drugset / Trial / NCT02660502

An Euglycemic Clamp Trial to Evaluate Pharmacokinetics of Single Doses of BioChaperone Insulin Lispro in Healthy Japanese Subjects

NCT02660502

Phase 1 Completed 15 enrolled Adocia Eli Lilly and Company · collab
RandomizedCrossoverQuadruple-blindTreatment

Summary

This is a double-blind, randomised, three period crossover phase 1 trial using automated 8-hour euglycemic clamps in healthy Japanese subjects. Each subject will be randomly allocated to one out of nine sequences to receive either three single doses of BioChaperone insulin lispro or one single dose of Humalog® and two single doses of BioChaperone insulin lispro on three separate dosing visits. The total trial maximum duration for a subject will be up to 10 weeks.

Timeline

Start
2016-01
Primary completion
2016-05
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Insulin Lispro Protein / enzyme biologic 0.1 iu/kg
Comparator Insulin Lispro Protein / enzyme biologic 0.2 iu/kg
Comparator Insulin Lispro Protein / enzyme biologic 0.4 iu/kg

Indications

No indication recorded.